1. Introduction {#sec1-molecules-23-01101}
===============

Atherosclerosis, a chronic inflammatory disease of the arterial wall, is a major cause of morbidity and mortality worldwide and is marked by the formation of atherosclerotic plaques \[[@B1-molecules-23-01101]\]. One critical event in the initiation of atherosclerotic plaques is the uptake of ox-LDL \[[@B2-molecules-23-01101]\]. LDL uptake is principally mediated by a variety of specific receptors including SR-A I/II, CD36, SR-BI, etc. \[[@B3-molecules-23-01101]\]. Recently, LOX-1 has been identified as the main endothelial receptor for ox-LDL \[[@B4-molecules-23-01101],[@B5-molecules-23-01101]\]. LOX-1 is a 50 KD transmembrane protein highly expressed on macrophages, vascular smooth muscle cells, and, especially, endothelial cells. It plays vital roles in the pathogenesis of atherosclerosis \[[@B6-molecules-23-01101]\]. Disturbance of LOX-1-mediated signaling pathways has been proposed as a potential strategy for anti-atherosclerotic drug discovery.

TLR4-MyD88 pathway leads to activation of the transcription factor NF-κB, thereby influencing inflammatory responses. Oxidative stress is characterized by an increased production of free oxygen radicals \[[@B7-molecules-23-01101]\]. Numerous clinical studies have demonstrated that oxidant stress is closely related to different risk factors of atherosclerosis such as hypercholesterolemia \[[@B8-molecules-23-01101]\], hypertension \[[@B9-molecules-23-01101]\], diabetes \[[@B10-molecules-23-01101]\], and smoking \[[@B11-molecules-23-01101]\]. Oxidative stress can promote conversion of LDL to atherogenic ox-LDL, contributing to the atherosclerotic plaque formation \[[@B12-molecules-23-01101]\]. Besides, oxidant stress is closely correlated with endothelial dysfunction \[[@B13-molecules-23-01101]\] and promotes vascular inflammatory response \[[@B14-molecules-23-01101]\]. Furthermore, TLRs-NF-κB pathway has been reported to participate in the anti-atherosclerotic effect of several natural products such as quercetin, pycnogenol, and procyanidins \[[@B15-molecules-23-01101],[@B16-molecules-23-01101],[@B17-molecules-23-01101]\].

Ursolic acid (UA) is a pentacyclic triterpenoid found in many herbs and spices like rosemary and thyme, especially in valuable Chinese medicinal herbs such as *Fructus Ligustrum lucidum* \[[@B18-molecules-23-01101]\] and *Forsythiae fructus* \[[@B19-molecules-23-01101]\]. It shows potentially beneficial activities in treating cardiovascular disease due to its anti-oxidative \[[@B14-molecules-23-01101]\], anti-inflammatory effects \[[@B20-molecules-23-01101]\], and other biological activities \[[@B21-molecules-23-01101],[@B22-molecules-23-01101]\]. However, it also demonstrates potential adverse effects. Messner et al. \[[@B1-molecules-23-01101]\] reported the pro-atherogenic effects of UA. There is a controversy around the effect of UA on atherosclerosis. This study is to investigate the effect of UA on cells in vitro; high-fat, diet-induced ApoE^−/−^ mice in vivo; and related mechanisms such as LOX-1 expression in endothelial cells. Our findings may supply a new sight for illustrating role of UA, which benefits the development of the anti-athrogenic drug.

2. Results {#sec2-molecules-23-01101}
==========

2.1. UA Decreased LPS-Induced LOX-1 Expression in HUVECs {#sec2dot1-molecules-23-01101}
--------------------------------------------------------

Firstly, the cytotoxic effect of UA on HUVECs was determined by MTT assay. Results showed that UA was cytotoxic to HUVECs at 50 μM ([Figure S1](#app1-molecules-23-01101){ref-type="app"}). To minimize the cytotoxic effect of UA on cell viability, 1 μM UA was chosen for further study. Compared with untreated HUVECs, 24 h stimulation with LPS increased LOX-1 expression at both mRNA and protein levels, which were dramatically inhibited by UA pretreatment ([Figure 1](#molecules-23-01101-f001){ref-type="fig"}B,C). Furthermore, immunofluorescence results showed that UA blocked LPS-induced LOX-1 expression localizing on the cell membrane ([Figure 1](#molecules-23-01101-f001){ref-type="fig"}D).

2.2. UA Inhibited LPS-Induced LOX-1 Expression via TLR4/MyD88 Pathway {#sec2dot2-molecules-23-01101}
---------------------------------------------------------------------

TLR4/MyD88 signal pathway is involved in LPS-induced inflammation \[[@B23-molecules-23-01101]\]. As expected, UA reversed LPS-induced TLR4 and MyD88 protein expressions ([Figure 2](#molecules-23-01101-f002){ref-type="fig"}A,B). Furthermore, silence of either TLR4 or MyD88 significantly decreased LOX-1 expression ([Figure 2](#molecules-23-01101-f002){ref-type="fig"}C,E).

2.3. UA Reduced ROS Generation and Decreased NF-κB Activity to Block LOX-1 Expression {#sec2dot3-molecules-23-01101}
-------------------------------------------------------------------------------------

ROS is one key signaling molecule involved in inflammation, and NF-κB pathway plays an essential role in LPS-induced LOX-1 expression in HUVECs \[[@B23-molecules-23-01101]\]. In this study, LPS induced ROS production and NF-κB activity, while UA pretreatment obviously reduced ROS generation and blocked translocation of p65 NF-κB into nucleus ([Figure 3](#molecules-23-01101-f003){ref-type="fig"}A--C). Furthermore, all NAC (ROS scavenger) and BAY (NF-κB inhibitor) inhibited LOX-1 expression ([Figure 3](#molecules-23-01101-f003){ref-type="fig"}D), hinting that UA blocked ROS/ NF-κB pathway to regulate LOX-1 expression.

2.4. UA Reduced Atherosclerotic Plaque Development in ApoE^−/−^ Mice {#sec2dot4-molecules-23-01101}
--------------------------------------------------------------------

Plaques formation and necrotic core areas occurrence are two key characteristics of atherosclerosis. In this study, both plaques and necrotic core areas were observed in artery of ApoE^−/−^ mice. UA administration significantly reduced plaque sizes as well as shrank necrotic core areas ([Figure 4](#molecules-23-01101-f004){ref-type="fig"}A,B).

2.5. UA Inhibited LOX-1 Expression in Thoracic Aorta of ApoE^−/−^ Mice {#sec2dot5-molecules-23-01101}
----------------------------------------------------------------------

LOX-1 was expressed at low level in aorta of WT mice but significantly increased in ApoE^−/−^ mice, which was dramatically decreased in UA pretreated mice ([Figure 5](#molecules-23-01101-f005){ref-type="fig"}).

3. Discussion {#sec3-molecules-23-01101}
=============

Due to the high life-threatening risk and severe financial burden of surgical treatment, pharmacological options for atherosclerosis therapy have always been discussed. UA, a natural pentacyclic triterpenoid carboxylic acid, is the major component of some traditional medicine herbs, although several studies have shown that UA has anti-inflammatory, anti-oxidative, and anti-diabetes functions \[[@B24-molecules-23-01101],[@B25-molecules-23-01101]\]. There are conflicting studies around its anti-atherosclerosis effect. LOX-1 is the primary receptor for ox-LDL uptake, which promotes key steps involved in atherosclerosis \[[@B26-molecules-23-01101],[@B27-molecules-23-01101],[@B28-molecules-23-01101],[@B29-molecules-23-01101]\]. In this study, LPS was chosen to induce endothelial LOX-1expression. UA decreased LOX-1 expression both in mRNA and protein levels, hinting that UA has potential anti-atherosclerosis activity.

Several lines of evidence support a role of oxidative stress in the pathogenesis of many diseases including atherosclerosis, tumor, Parkinson's disease, and so on \[[@B30-molecules-23-01101],[@B31-molecules-23-01101]\]. UA has been proved to own anti-oxidative effects. Experiment data showed that UA significantly reduced ROS generation, and ROS scavenger obviously decreased LOX-1 expression.

NF-κB plays a critical role in regulating inflammation and performs an important function in LPS-induced LOX-1 expression \[[@B23-molecules-23-01101]\]. UA has been proved to own anti-inflammatory effects \[[@B32-molecules-23-01101]\]. In this study, UA blocked p65NF-κB translocated into nucleus. Furthermore, NF-κB inhibitor decreased endothelial LOX-1 expression, suggesting the importance of NF-κB for regulating LOX-1.

The present findings in vitro allowed us to postulate that UA exhibited anti-atherosclerosis action in vivo. To verify this hypothesis, we detected the effects of UA on high-fat-diet-fed ApoE^−/−^ mice. The experiments showed that oral administration of UA for 12 weeks dramatically reduced plaque sizes and the shrinkage of necrotic core areas occurred in model ApoE^−/−^ mice providing the direct evidence for its anti-atherosclerotic effect. Besides, consistent with the in vitro results, expression of LOX-1 in the aorta was also decreased by UA, suggesting that LOX-1 is a promising therapeutic target in atherosclerosis for UA in future.

4. Materials and Methods {#sec4-molecules-23-01101}
========================

4.1. Materials and Reagents {#sec4dot1-molecules-23-01101}
---------------------------

UA (purity \> 98%) was purchased from Chengdu Herbpurify Co. Ltd. (Chendu, China). Hoechst 33342, *N*-acetyl cysteine (NAC), LPS (Escherichia coli serotype 055:B5, LPS), 5-(6)-carboxy-2′, 7′-dichlorodihydrofluorescein diacetate (DCFH~2~-DA), and BAY11-7082 were purchased from Sigma Aldrich (St. Louis, MO, USA). Antibodies for TLR4, MyD88 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies for NF-κB p65, GAPDH, and Histone H3 were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-LOX-1 antibody was obtained from R&D (Minneapolis, MN, USA). The BCA protein kits were purchased from Thermo Fisher (Suwanee, GA, USA). SiRNAs for TLR4, MyD88 were purchased from Gene Pharma Company (Shanghai, China). Oil Red O Staining Kit and HE Staining Kit were obtained from Nanjing Jiancheng Bioengineering Research Institute (Nanjing, China).

4.2. Cell Culture {#sec4dot2-molecules-23-01101}
-----------------

Human umbilical vein endothelial cells (HUVECs) (Gibco, Life Technologies Corp., Carlsbad, CA, USA) were cultured in Vascular Cell Basal Medium with Endothelial Cell Growth Kit-BBE at 37 °C in a humidified atmosphere of 5% CO~2~. Before passaging cells, issue culture flasks, 96-well plates, and 6-well plates were pre-coated with 0.1% gelatin. All assays were conducted using low cell passage cells (2--5 passages).

4.3. Animal Experiment {#sec4dot3-molecules-23-01101}
----------------------

Male ApoE^−/−^ mice (6--8 weeks old) on C57BL/6J background and age-matched wild-type C57BL/6J controls were purchased from Beijing HFK Bioscience Co., Ltd. (Beijing, China). Mice were housed in SPF-grade animal facilities with a 12 h light/dark cycle at 23 °C (±2 °C). All animal procedures follow the NIH guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23, revised 1978). Starting from 6 weeks, the mice were fed with a HCD (54.35% raw grain, 20% lard, 0.15% cholesterol, 15% sucrose, 0.5% Sodium Cholate, and 10% yolk powder) for 12 weeks. All ApoE^−/−^ mice were dosed daily via intragastric gavage with 100 mg·kg^-1^·day^−1^ UA and 25 mg·kg^−1^·day^−1^ simvastatin dissolved in 0.5% CMC-Na or administered 0.5% CMC-Na alone (vehicle control) (*n* = 8 per group).

4.4. Immunofluorescence Assay {#sec4dot4-molecules-23-01101}
-----------------------------

Cells (1 × 10^4^ cells/well) were seeded on glass slides in 96-well plates. After LPS treatment (with or without UA pretreatment), the slides were fixed with 4% PFA for 30 min. Then, the slides were permeabilized with PBS-T (containing 0.1% Triton x-100 in PBS solution) and blocked with PBS-B (containing 4% BSA in PBS solution). After being incubated with primary antibody (1:1000) and secondary antibody (1:5000), cells were stained with Hoechst 33342 in dark for 5 min. The protein location and expression were observed with IN Cell Analyzer 2000 (GE Healthcare).

4.5. Western Blotting {#sec4dot5-molecules-23-01101}
---------------------

Treated HUVECs were washed twice with ice-cold PBS and lysed with RIPA buffer supplemented with a protease cocktail and phosphatase inhibitors. The cell lysates were separated using 8--10% SDS-PAGE and transferred onto PVDF membranes. After being blocked with 5% non-fat milk in TBST (20 mM Tris-HCl, 500 mM NaCl, and 0.1% Tween 20) at room temperature for 2 h, membranes were incubated with specific primary antibodies and secondary antibodies. The protein-antibody complexes were detected by ECL Advanced Western Blot Detection Kit. The intensity of the band was quantitated with Quantity One software (Bio-Rad).

4.6. SiRNA Transfection {#sec4dot6-molecules-23-01101}
-----------------------

Gene silencing experiment of TLR4, MyD88 with siRNA was performed according to our previous report \[[@B23-molecules-23-01101]\]. Briefly, cells (1.0 × 10^6^/well) were seeded in 6-well plate overnight. 100 pM siRNA was diluted in 100 μL Opti-MEM reduced serum medium in each well and then mixed gently. Similarly, 5 μL of Lipofectamine TM 2000 was diluted in 100 μL of Opti-MEM reduced serum medium and mixed gently. After incubation for 5 min at room temperature, the diluted siRNA and diluted lipofectamine (total volume 200 μL) were mixed gently and incubated for another 20 min at room temperature. Further, siRNA-lipofectamine complex (200 μL) was added to each well. After incubation for 4 h, the complexes were discarded and cells were cultured with completed medium.

4.7. Real-Time RT-PCR {#sec4dot7-molecules-23-01101}
---------------------

The mRNA expression of LOX-1 was determined with real-time PCR as our previous report \[[@B23-molecules-23-01101]\]. Briefly, total RNA was extracted using TRIzol reagent (Life Technologies, USA). cDNA was synthesized by reverse transcription (RT) using GoScript™ Reverse Transcription System (Promega, Madison, WY, USA). Quantitative real-time PCR was carried out on Stratagene Mx3005P (Agilent Technologies, Santa Clara, CA, USA) using GoTaq^®^ qPCR Master Mix (Promega, USA). The primer sequences used in this experiment are listed for LOX-1: 5′-TGGGAAAAGAGCCAAGAGAA-3′ (forward), 5′- TAAGTGGGGCATCAAAGGA' (reverse); anf for GAPDH: 5′-AGAAGGCTGGGGCTCATTTG-3′ (forward), 5′-AGGGGCCATCCACAGTCTTC-3′ (reverse). The levels of LOX-1 expression were determined by normalizing to GAPDH expression.

4.8. Aorta Collection and Lesion Size Evaluation {#sec4dot8-molecules-23-01101}
------------------------------------------------

To evaluate plaque extension, frozen sections of the aortic sinus (8 mm) were stained using Oil Red O, hematoxylin, and eosin (H&E), respectively. Related experiments were performed following the method of Paigen et al. \[[@B33-molecules-23-01101]\]*.*

4.9. Statistical Analysis {#sec4dot9-molecules-23-01101}
-------------------------

Twenty four ApoE^−/−^ mice were randomly allocated to groups and equal group sizes were obtained (*n* = 8 per group). Data were expressed as the means ± SD. The differences between groups were analyzed using Prism 5.0 (Graph Pad Software Inc., San Diego, CA, USA), and the statistical analysis was performed by analysis of variance (one-way ANOVA) followed by Student Newman--Keuls test.

5. Conclusions {#sec5-molecules-23-01101}
==============

In summary, this study showed that natural product-UA inhibited NF-κB-mediated LOX-1 expression both in vivo and in vitro through ROS generation. In view of the key roles of LOX-1 in the pathogenesis of atherosclerosis, inhibition of LOX-1 contributed to the anti-atherosclerotic effect of UA. Our study demonstrates that UA showed the effect of ameliorating atherosclerosis and put forward the potential mechanism. It supplies a new sight to illustrate the mechanism of action of UA for attenuates atherosclerosis in mice.
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![The structure of UA (**A**); Cells were pretreated with UA (1 μM) for 1 h and then stimulated with LPS (5 mg/mL) for 24 h; LOX-1 mRNA (**B**), protein (**C**), and localization on the membranes (**D**) were detected by real-time PCR, western blotting, and immunofluorescence (60×), respectively. UA, ursolic acid.](molecules-23-01101-g001){#molecules-23-01101-f001}

![Cells were pretreated with UA (1 μM) for 1 h and then stimulated by LPS (5 mg/mL) for 24 h; expressions of TLR4 and MyD88 were determined by western blotting (**A**,**B**). Cells were transfected with siRNAs for TLR4 (**C**) and MyD88 (**D**) and then stimulated with LPS (5 mg/mL) for 24 h and the LOX-1 expression were determined by western blotting (**E**). Cont, control; NC-siRNA, negative control siRNA. UA, ursolic acid; N.S, no significant differences.](molecules-23-01101-g002){#molecules-23-01101-f002}

![Cells were treated with LPS (5 mg/mL) for 4 h after pretreatment with UA (1 μM) or NAC (5 mM) for 1 h; ROS was determined by DCFH~2~-DA (**A**); Cells were treated with LPS (5 mg/mL) for 24 h with or without pretreatment with UA (1 μM), NAC (5 mM), or BAY (10 μM) for 1 h, and expression of p65 (**B**) and LOX-1 (**D**) was detected by western blotting; Cells were treated with LPS (5 mg/mL) with or without 1 h pretreatment with UA (1 μM) and NAC (5 mM), and p65 NF-κB localization was determined by immunofluorescence (**C**) (60×). UA, ursolic acid; BAY, BAY11-7082; NAC, N-acetyl cysteine.](molecules-23-01101-g003){#molecules-23-01101-f003}

![Aortic sinus sections were stained with Oil Red O and H&E to detect plaque sizes (40×) (**B**) and necrotic core areas (40×) (**A**), respectively. UA, ursolic acid; WT, wild type; ApoE^−/−^, apolipoprotein E-deficient.](molecules-23-01101-g004){#molecules-23-01101-f004}

![Expression of LOX-1 in the aorta was detected by immunofluorescence (4×). WT, wild type; ApoE^−/−^, apolipoprotein E-deficient; UA, ursolic acid.](molecules-23-01101-g005){#molecules-23-01101-f005}
